Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipragliflozin vs Glimepiride in T2DM with Albuminuria
NCT03118713Phase 4Terminated
- Sponsor
- Astellas Pharma
- Start
- Apr 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ipragliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Percentage of change of Urine Albumin-to-Creatinine Ratio at 24 weeks. Started Apr 2017; status: terminated.
02
Drugs
ipragliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03118713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118713.